Citigroup
FHTX icon

Citigroup’s Foghorn Therapeutics FHTX Stock Holding History

Citigroup’s Portfolio FHTX Stock Details FHTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$90.5K Buy
18,544
+15,129
+443% +$67.1K ﹤0.01% 4737
2026
Q1 		$16.3K Buy
3,415
+1,085
+47% +$5.96K ﹤0.01% 4886
2025
Q4 		$12.6K Sell
2,330
-22
-0.9% -$100 ﹤0.01% 4993
2025
Q3 		$11.5K Sell
2,352
-10,309
-81% -$54.7K ﹤0.01% 4980
2025
Q2 		$59.5K Sell
12,661
-6,173
-33% -$25.8K ﹤0.01% 4666
2025
Q1 		$68.7K Sell
18,834
-1,198
-6% -$5.46K ﹤0.01% 4782
2024
Q4 		$94.5K Buy
20,032
+1,687
+9% +$12.3K ﹤0.01% 4867
2024
Q3 		$171K Buy
18,345
+12,744
+228% +$92.3K ﹤0.01% 4447
2024
Q2 		$32.2K Buy
5,601
+2,216
+65% +$13.2K ﹤0.01% 4824
2024
Q1 		$22.7K Buy
3,385
+452
+15% +$2.51K ﹤0.01% 4989
2023
Q4 		$18.9K Buy
2,933
+2,388
+438% +$10.3K ﹤0.01% 5009
2023
Q3 		$2.73K Sell
545
-6,233
-92% -$48K ﹤0.01% 4881
2023
Q2 		$47.7K Buy
6,778
+6,301
+1,321% +$44.1K ﹤0.01% 4674
2023
Q1 		$2.96K Sell
477
-188
-28% -$1.23K ﹤0.01% 5039
2022
Q4 		$4.24K Buy
665
+360
+118% +$2.71K ﹤0.01% 5075
2022
Q3 		$3K Sell
305
-994
-77% -$12.8K ﹤0.01% 5378
2022
Q2 		$18K Buy
1,299
+476
+58% +$6.14K ﹤0.01% 5057
2022
Q1 		$13K Sell
823
-4,164
-83% -$57.1K ﹤0.01% 5391
2021
Q4 		$114K Buy
4,987
+2,756
+124% +$39.6K ﹤0.01% 4661
2021
Q3 		$31K Buy
2,231
+1,301
+140% +$14.4K ﹤0.01% 5006
2021
Q2 		$10K Buy
930
+453
+95% +$4.94K ﹤0.01% 5652
2021
Q1 		$6K Sell
477
-852
-64% -$14K ﹤0.01% 5847
2020
Q4 		$27K Buy
+1,329
New +$25.5K ﹤0.01% 6460

Other funds holding FHTX

FP
Flagship Pioneering Cambridge, Massachusetts $1.54B AUM 86.39% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Raymond James Financial
Raymond James Financial St Petersburg, Florida $369B AUM 28.27% 1-Year Est. Return
EC
Euclidean Capital New York $440M AUM 28.33% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

Citigroup's FHTX Position: Q2 2026 in Review

Citigroup increased its Foghorn Therapeutics (FHTX) stake by 443% in Q2 2026, buying an estimated $67.1K and bringing the position to 18,544 shares worth $90.5K. The position accounts for ﹤0.01% of the portfolio, ranked #4737.

Citigroup first reported a position in FHTX in Q4 2020 and has held it in 23 quarters since. The position peaked at $171K in Q3 2024. 102 funds tracked by Wall St. Rank hold FHTX as of Q2 2026.

  • Citigroup held 18,544 shares of Foghorn Therapeutics worth $90.5K as of Q2 2026.
  • Citigroup bought 15,129 Foghorn Therapeutics shares in Q2 2026, an estimated $67.1K.
  • Foghorn Therapeutics made up ﹤0.01% of Citigroup's portfolio in Q2 2026, its #4737 holding.
  • Citigroup first reported a position in Foghorn Therapeutics in Q4 2020 and has held it in 23 quarters since.
  • Citigroup's Foghorn Therapeutics position peaked at $171K in Q3 2024.
  • 102 funds tracked by Wall St. Rank held Foghorn Therapeutics as of Q2 2026.

Based on Citigroup's 13F filing for Q2 2026, filed 3 Aug 2026.